カテゴリ： GlobalData, インド, 企業調査

Biocon Ltd (BIOCON)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9873
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：87
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：インド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. It also provides research services including discovery, development and manufacturing services for both small and large molecules. Biocon provides research solutions to the biotechnology and pharmaceutical companies worldwide. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd (BIOCON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Venture Financing 16
Syngene May Raise Over USD50 Million in Venture Financing 16
Private Equity 17
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Partnerships 22
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Licensing Agreements 34
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Equity Offering 42
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Asset Transactions 45
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd – Key Competitors 46
Biocon Ltd – Key Employees 47
Biocon Ltd – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Joint Venture 48
Recent Developments 50
Strategy And Business Planning 50
Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia 50
Financial Announcements 51
Oct 25, 2018: Biocon announces financial results for the second quarter ended on September 30th, 2018 51
Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 54
Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd] 57
Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 60
Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore 63
Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 67
Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 70
Legal and Regulatory 73
Sep 22, 2018: Biocon’s drug substance facility in bangalore completes US FDA inspection with No observations 73
Jul 04, 2018: Biocon’s Sterile Drug Product facility Receives EU GMP Certification 74
Jun 23, 2018: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA 75
May 02, 2018: Biocon Regulatory Audit Update 76
Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 77
Feb 21, 2018: Biocon Announces US-FDA Inspection at Malaysian Manufacturing Facility 78
Nov 20, 2017: Biocon’s Drug product Facility Receives EIR with VAI status, Inspection Closed 79
Sep 18, 2017: Biocon’s Facility in Vishakhapatnam completes USFDA Inspection with no observations 80
Jul 09, 2017: Biocon provides update on Bangalore Facility 81
Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 82
May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 83
Other Significant Developments 84
Dec 13, 2017: Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee” 84
Oct 06, 2017: Biocon: No Separate Audit or Observations by Health Canada 85
May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Syngene May Raise Over USD50 Million in Venture Financing 16
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd, Key Competitors 46
Biocon Ltd, Key Employees 47
Biocon Ltd, Subsidiaries 48
Biocon Ltd, Joint Venture 48

List of Figures
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Biocon Ltd (BIOCON)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)：医療機器：M&Aディール及び事業提携情報
    Summary Jiangsu Yuyue Medical Equipment & Supply Co Ltd (Jiangsu Yuyue) is a medical device company that manufactures and distributes various medical equipments. The company’s products include electronic blood pressure monitor, air sterilization purifier, X-ray machine, blood glucose meter, temperat …
  • Nova Scotia Power Inc：電力：M&Aディール及び事業提携情報
    Summary Nova Scotia Power Inc (NSP) a subsidiary of Emera Inc is a electric utility that provides electricity distribution services. The utility uses a fuel mix including hydro, tidal, wind, coal, oil, biomass and natural gas to generate electricity. It offers a range of home heating options, includ …
  • Crossbeta Biosciences BV：製薬・医療：M&Aディール及び事業提携情報
    Summary Crossbeta Biosciences BV (Crossbeta) is a biotech company that offers drug discovery programs for the treatment of misfolded protein diseases. The company develops drugs against Alzheimer’s, Parkinson’s, Huntington’s disease and ALS. It offers screening of oligomer-specific therapeutics and …
  • Kelda Group Ltd：企業の戦略・SWOT・財務情報
    Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GS Engineering & Construction Corp (006360)：企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • China Gezhouba Group Co Ltd (600068)：電力：M&Aディール及び事業提携情報
    Summary China Gezhouba Group Co Ltd (CGGC) is an engineering, procurement and construction (EPC) company. It provides a wide range of services including dredging, foundation works, building construction, engineering survey, designing, construction management and consultancy, and relevant technology …
  • JPMorgan Chase & Co.：企業の戦略・SWOT・財務情報
    JPMorgan Chase & Co. - Strategy, SWOT and Corporate Finance Report Summary JPMorgan Chase & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bosideng International Holdings Limited：企業の戦略・SWOT・財務分析
    Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Vigo Coal Company Incorporated：企業の戦略・SWOT・財務情報
    Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Iron Mountain Incorporated：企業のM&A・事業提携・投資動向
    Iron Mountain Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iron Mountain Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Tyser & Co Limited：企業の戦略的SWOT分析
    Tyser & Co Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • New Gold Inc.：企業のM&A・事業提携・投資動向
    New Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Novasep Holding SAS-製薬・医療分野：企業M&A・提携分析
    Summary Novasep Holding SAS (Novasep), formerly Groupe Novasep SAS is a pharmaceutical company which offers services in molecule production and purification for life science and chemical industries. The company offers contract manufacturing and development, custom manufacturing, process engineering, …
  • Versantis AG：製薬・医療：M&Aディール及び事業提携情報
    Summary Versantis AG (Versantis) is a pharmaceutical company that develops new generation of medicines and diagnostics for treating patients with liver diseases. The company’s pipeline product includes VS-01, a liposomal-based peritoneal dialysis fluid that acts as a clearance enhancer for a large s …
  • TapImmune Inc (TPIV)：企業の財務・戦略的SWOT分析
    Summary TapImmune Inc (TapImmune) is a clinical-stage immuno-oncology company focus on the development of innovative peptide, gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company’s pipeline products include TPIV 200, which is intended for the tre …
  • EBSCO Industries Inc：企業の戦略的SWOT分析
    EBSCO Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Alliance Data Systems Corporation：企業の戦略・SWOT・財務分析
    Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • San Leon Energy Plc (SLE)：石油・ガス：M&Aディール及び事業提携情報
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • Vascular Biogenics Ltd (VBLT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • FUDAN University-製薬・医療分野：企業M&A・提携分析
    Summary FUDAN University (FUDAN) is an educational university that offers bachelor, undergraduate, master and doctoral degrees in various disciplines. The university confers bachelor's degrees in multiple academic disciplines. It conducts research in various disciplines such as natural sciences, dep …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆